Compare ACADIA Pharmaceuticals Inc. (ACAD) vs United States Copper Index Fund (CPER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs United States Copper Index Fund — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while United States Copper Index Fund trades at $37.06. Which is the better fit depends on your goals.
| ACAD | CPER | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $28.06 | $40.60 |
52-Week Low | $20.06 | $27.21 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
CPER, the United States Copper Index Fund ETF, trades at $37.84, up 1.47% today. The technical outlook is mixed, with a bullish moving average signal but neutral overall momentum. Recent news highlights strong copper demand from AI and electric vehicles, though supply constraints and price volatility are key themes. Financial ratios are not applicable as this is a commodity ETF tracking copper futures.
The outlook for CPER is tied to copper's structural bull market, driven by AI and green energy demand. Risks include global manufacturing weakness and commodity price swings. Investor sentiment is positive due to copper's supply-demand imbalance, but the ETF's performance remains sensitive to macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →
